Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucosidase, alpha | Starlite/ChEMBL | No references |
Saccharomyces cerevisiae | Rce1p | Starlite/ChEMBL | No references |
Homo sapiens | muscleblind-like splicing regulator 1 | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | Ras converting CAAX endopeptidase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Brugia malayi | hypothetical protein | Ras converting CAAX endopeptidase 1 | 225 aa | 181 aa | 21.6 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | CAAX prenyl protease family | 0.0221 | 0.7322 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0046 | 0 | 0.5 |
Echinococcus granulosus | lysosomal alpha glucosidase | 0.0197 | 0.6298 | 0.1555 |
Brugia malayi | Glycosyl hydrolases family 31 protein | 0.0197 | 0.6298 | 0.6093 |
Mycobacterium tuberculosis | Probable conserved integral membrane protein | 0.0046 | 0 | 0.5 |
Mycobacterium ulcerans | integral membrane protein | 0.0046 | 0 | 0.5 |
Trypanosoma cruzi | CAAX prenyl protease 2, putative | 0.0221 | 0.7322 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0046 | 0 | 0.5 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0197 | 0.6298 | 0.1555 |
Mycobacterium ulcerans | hypothetical protein | 0.0046 | 0 | 0.5 |
Onchocerca volvulus | 0.0114 | 0.284 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0221 | 0.7322 | 0.3891 |
Trypanosoma cruzi | peptidase with unknown catalytic mechanism (family U48) | 0.0221 | 0.7322 | 0.5 |
Treponema pallidum | hypothetical protein | 0.0046 | 0 | 0.5 |
Echinococcus multilocularis | CAAX prenyl protease 2 | 0.0221 | 0.7322 | 0.3891 |
Trypanosoma brucei | CAAX amino terminal protease, putative | 0.0221 | 0.7322 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0221 | 0.7322 | 0.5 |
Leishmania major | CAAX prenyl protease 2, putative,peptidase with unknown catalytic mechanism (family U48) | 0.0221 | 0.7322 | 0.5 |
Mycobacterium tuberculosis | Probable integral membrane protein | 0.0046 | 0 | 0.5 |
Trichomonas vaginalis | Clan U, family U48, CaaX prenyl peptidase 2-like | 0.0221 | 0.7322 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 1 | 1 |
Echinococcus granulosus | CAAX prenyl protease 2 | 0.0221 | 0.7322 | 0.3891 |
Schistosoma mansoni | family U48 unassigned peptidase (U48 family) | 0.0221 | 0.7322 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0046 | 0 | 0.5 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 1 | 1 |
Chlamydia trachomatis | hypothetical protein | 0.0046 | 0 | 0.5 |
Plasmodium falciparum | protease, putative | 0.0046 | 0 | 0.5 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 1 | 1 |
Toxoplasma gondii | CAAX amino terminal protease family protein | 0.0046 | 0 | 0.5 |
Schistosoma mansoni | alpha-glucosidase | 0.0169 | 0.5156 | 0.6814 |
Brugia malayi | Muscleblind-like protein | 0.018 | 0.5616 | 0.5373 |
Mycobacterium tuberculosis | Probable conserved integral membrane protein | 0.0046 | 0 | 0.5 |
Loa Loa (eye worm) | glycosyl hydrolase family 31 protein | 0.0197 | 0.6298 | 0.1555 |
Schistosoma mansoni | family U48 unassigned peptidase (U48 family) | 0.0221 | 0.7322 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0046 | 0 | 0.5 |
Schistosoma mansoni | alpha-glucosidase | 0.0169 | 0.5156 | 0.6814 |
Brugia malayi | CAAX amino terminal protease family protein | 0.0221 | 0.7322 | 0.7173 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0197 | 0.6298 | 0.1555 |
Plasmodium vivax | protease, putative | 0.0046 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (binding) | = 5.17 uM | PUBCHEM_BIOASSAY: Human Ras-Converting Enzyme Inhibition Assay Measured in Biochemical System Using Plate Reader - 2034-04_Inhibitor_Dose_CherryPick_Activity. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2618] | ChEMBL. | No reference |
AC50 (binding) | = 7.988 uM | PUBCHEM_BIOASSAY: Ras-converting Enzyme/Cell Proliferation Pathway Measured in Biochemical System Using Plate Reader - 2034-01_Inhibitor_Dose_CherryPick. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2618] | ChEMBL. | No reference |
Potency (functional) | 0.0657 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 0.631 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | 12.5893 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 37.933 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.